and for those tesamorelin-treated patients completing the 26-week treatment period that were re-randomized to tesamorelin (T-T group) or re-randomized to placebo, 36.6% and 32.0%, respectively, had impaired glucose tolerance, while 2.0% re-randomized to tesamorelin and 6.0% re-randomized to placebo had diet-controlled diabetes mellitus
What is the optimal microdosing protocol for retatrutide?
Additionally, tirzepatide-induced appetite suppression might mask appetite changes that could otherwise signal medication intolerance or disease progression
Results older than six months are typically repeated before initiating treatment, since metabolic markers can change meaningfully in that window
De Angelis, M., Anichini, G., Palamara, A